Top

News & Events

HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology

HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology

• Four poster presentations expand evidence on potent T cell responses, ability to break tolerance and potential combination use beyond PD-1 inhibitors

• Preclinical data suggest synergy of arenaviral immunotherapy with 4-1BB agonists or cell therapy, resulting in better tumor control and more responders

• Data highlight the broad potential of HOOKIPA’s novel arenaviral platform technology in different cancer types and treatment combinations


New York, US and Vienna, Austria, March 08, 2022 - HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that preclinical, translational, and clinical biomarker data from its oncology pipeline have been selected for four poster presentations at the 2022 American Association for Cancer Research Annual Meeting (AACR), taking place April 8-13.

“We’re thrilled to have four poster presentations accepted at AACR as they provide further evidence of the broad potential of our arenaviral platform to address unmet needs in various types of cancer, either alone or in combination with other modalities,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “New translational data from our ongoing Phase 1/2 trial in head and neck cancers continue to show strong T cell responses, and new preclinical data further support our early-stage prostate cancer program, as well as highlight new potential combination approaches.”

The AACR posters provide a broad preclinical, translational, and clinical biomarker dataset highlighting the versatility and therapeutic utility of replicating arenavirus vectors to activate and augment tumor-specific CD8+ T cell responses for tumor killing. Specifically, the data support the potential of arenaviral vectors to target self and non-self tumor antigens and be used as monotherapy or in combination with other modalities. The abstracts are available on the AACR website here.

  •  Abstract # 2038: In vitro and in vivo characterization of non-oncolytic engineered arenavirus for cancer immunotherapy
    This detailed preclinical and translational characterization of arenavirus vectors based on Lymphocytic choriomeningitis virus and Pichinde virus shows anti-tumor effects in preclinical models, as well as infection and activation of human professional antigen-presenting cells key for eliciting a robust tumor specific CD8+ T cell response.
    - In person poster presentation
    - Monday, April 11, 1:30pm – 5:00pm CT
    - Presenter: Henning Lauterbach, HOOKIPA

     
  • Abstract #3284: HB-201 and HB-202, an arenavirus-based immunotherapy, induces tumor T cell infiltration in patients with HNSCC and other HPV16+ tumors
    These data demonstrate that HB-201 and HB-202/HB-201 rapidly induce unprecedented levels of systemic, tumor-specific CD8+ T cells in patients with Human Papilloma Virus 16-positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) after one dose. In addition, the data show a sustained polyfunctional profile of these cells during treatment, infiltration of CD8+ T cells into tumors and decrease of HPV16+ DNA in tumor tissue, in line with the proposed mode of action of the therapy.
    - In person poster presentation
    - Tuesday, April 12, 1:30pm – 5:00pm CT
    - Presenter: Henning Lauterbach, HOOKIPA

     
  • Abstract # 3298: Propagation competence of a self-antigen-targeting arenavirus vector-based cancer therapy determines antitumor efficacy in mouse melanoma
    These data highlight the crucial role of replication competence of arenavirus-based vectors for: overcoming immune tolerance; robust induction of CD8+ T cell responses against tumor self-antigens; and activation and amplification of adoptively transferred TCR transgenic CD8+ T cells in a combination therapy which proved able to induce complete tumor remission in mice.
    - In person poster presentation
    - Tuesday, April 12, 1:30pm – 5:00pm CT
    - Presenter: Klaus Orlinger, HOOKIPA

     
  • Abstract # 4198: Evaluation of a cancer immunotherapy with engineered arenavirus vectors and 4-1BB agonists in a preclinical tumor model
    The data demonstrate one strategy to unlock the potential of arenavirus vector-induced CD8+ T cell responses for tumor killing in a combination therapy with 4-1BB agonists.
    - In person poster presentation
    - Wednesday, April 13, 9:00am – 12:30pm CT
    - Presenter: Judith Strauss, HOOKIPA

 

 

 

back to news

People

Melanie Toyne-SewellManaging Partner

Agnes StephensAccount Director